Triptodur™ (triptorelin) – New drug approval
June 30, 2017 – Arbor Pharmaceuticals announced the FDA approval of Triptodur (triptorelin) extended-release injectable suspension for the treatment of pediatric patients ≥ 2 years of age with central precocious puberty (CPP).
Download PDF
